Optimising Treatment Regimens For Severe Malaria
Grant number: 1025319 | Funding period: 2012 - 2015
Every year, severe malaria kills up to 800,000 people worldwide. To prevent death, a patient must be treated promptly and effectively. Children and adults vary in terms of their response to a malaria drug, and therefore may require a different dosing regimen. We will perform a rigorous analytical assessment of antimalarial drug concentration and efficacy data to determine dosing regimens. This will improve the treatment of severe malaria, and thereby, reduce malaria-related mortality.
Related publications (3)
Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria.
SG Zaloumis, J Tarning, S Krishna, RN Price, NJ White, TME Davis, JM McCaw, P Olliaro, RJ Maude, P Kremsner, A Dondorp, M Gomes, K Barnes, JA Simpson
There are ~660,000 deaths from severe malaria each year. Intravenous artesunate (i.v. ARS) is the first-line treatment in adults a..